Clinical Trial Update: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating belantamab mafodotin in multiple myeloma patients with varying hepatic function has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 1 | Status: WITHDRAWN